Dale Wallington
Psychiatry · West Hartford, CTNPI 1609838689
Payments from drug & device makers
Across 1,131 payments — averaging $27.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Indivior Inc.$6K
- AbbVie$6K
- Takeda Pharmaceuticals U.S.A., Inc.$3K
- Johnson & Johnson$2K
- Teva Pharmaceuticals USA, Inc.$2K
- Neurocrine Biosciences, Inc.$1K
- plus $12K from 33 others
What the payments were for
- Speaking & faculty fees$9,60031%
- Travel & lodging$1,0483%
- Food & beverage$20,55766%
- Education$1300%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SUBLOCADE$6,002
- VRAYLAR$2,725
- TRINTELLIX$1,800
- SPRAVATO$125
How this compares
$31,335 in reported general payments places this provider in the 90th percentile of 644 psychiatry providers in Connecticut.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 15 | $126,286 |
| VraylarCariprazine Hcl | 56 | $85,841 |
| TrintellixVortioxetine Hydrobromide | 42 | $37,102 |
| RexultiBrexpiprazole | 22 | $34,502 |
| BelsomraSuvorexant | 59 | $28,526 |
| QelbreeViloxazine Hcl | 16 | $11,464 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 119 | $11,170 |
| VyvanseLisdexamfetamine Dimesylate | 15 | $9,528 |
| QuviviqDaridorexant Hcl | 15 | $7,440 |
| Methylphenidate ErMethylphenidate Hcl | 16 | $5,696 |
| Bupropion XlBupropion Hcl | 188 | $5,381 |
| Duloxetine Hcl | 184 | $4,832 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 44 | $4,449 |
| Lurasidone Hcl | 18 | $4,290 |
| Quetiapine Fumarate ErQuetiapine Fumarate | 14 | $3,988 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $1,448 | $126,28615 claims |
| AbbVieVraylar | $5,689 | $85,84156 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $2,725 | $46,63057 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $958 | $34,50222 claims |
| MerckBelsomra | $217 | $28,52659 claims |
| Supernus Pharmaceuticals, Inc.Qelbree | $450 | $11,46416 claims |
| Idorsia Pharmaceuticals US IncQuviviq | $314 | $7,44015 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 644 psychiatry providers in Connecticut.
Other psychiatry in West Hartford
- Irene AbramovichWest Hartford$352K
- John NazarianWest Hartford$79K
- Vladimir CoricNew Haven$133.7M
- Christopher VandyckNew Haven$20.8M
- Bart SloanNorwalk$6.8M
- Adam MeccaNew Haven$5.1M
- David MatuskeyFarmington$3M
- Donald AmmermanDanbury$1.5M
- Mahmoud OkashaNorwich$1.4M
- Gerard SanacoraNew Haven$1.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.